About Napo Pharma
Napo Pharma is a Healthcare company based in San Francisco (United States) founded in 2001 by Lisa Conte, and was acquired by Jaguar Health in February 2017. Small molecule therapeutics for diarrheal diseases are developed. Napo Pharma has raised $5.14 million across 17 funding rounds from investors including Jaguar Health and Kingdon Capital Management. Its chief executive, as recorded, is Lisa Conte. Napo Pharma offers products and services including Mytesi® and NP-300. Its focus areas include Life Sciences, Gastroenterology, Drugs and Diarrhea. Its legal entity in India is Napo India Private Limited (U24239MH2005FTC158447).
Company details
Napo Pharmaceuticals was founded in 2001 in San Francisco, United States, where small molecule therapeutics are developed and commercialized for international markets. Emphasis is placed on treatments for diarrheal diseases. Crofelemer has been approved for diarrhea associated with HIVAIDS and licensed to Glenmark and Salix Pharma. Pipeline candidates target insulin-resistant diseases, diarrhea-predominant IBS, acute infectious diarrhea, and pediatric diarrhea.
- Headquarters San Francisco, United States
- Founders Lisa Conte
- Stage Acquired
- SectorsHealthcare
- Website napopharma.com
- Social LinkedIn X Facebook
- Acquired by Jaguar Health (Feb 2017)
- Legal Name Napo India Private Limited
- Date of Incorporation 29 Dec, 2005
- Jurisdiction Navi Mumbai, Maharashtra, India
- Indian entity net loss-₹41.3 Lakh
FY 2015 · 0% margin
- Indian entity EBITDA-₹41 Lakh
FY 2015 · 0% margin
- Total Equity Funding$5.14M (USD)
in 17 rounds
- Latest Funding Round$2M (USD), Post-IPO
Jan 2017
- InvestorsJaguar Health
& 1 more
- Acquired byJaguar Health
(Feb 2017)
Associated legal entities of Napo Pharma
Napo Pharma operates through Napo India Private Limited (strike off). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2015) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Napo India Private Limited CIN U24239MH2005FTC158447 | Strike Off | 29 Dec 2005 | Navi Mumbai, Maharashtra | 2 | View details |
Products & Services of Napo Pharma
Napo Pharma offers a comprehensive portfolio of products and services, including Mytesi® and NP-300.
Treats chemotherapy-induced overactive bowel and related symptoms.
Targets gastrointestinal disorders through novel mechanisms.
Funding Insights of Napo Pharma
Napo Pharma has successfully raised a total of $5.14M across 17 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.14M
- Total Rounds 17
- Last Round Post-IPO — $2M
- First Round $1.55M
(Sep 2002)
- Investors Count 1
Latest 10 of 17 funding rounds of Napo Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2017 | $2M | Post-IPO | – | – | |
| Jun 2014 | $137,500 | Post-IPO | – | – | – |
| Oct 2011 | $3.09M | Post-IPO | – | – | – |
| Apr 2011 | $3M | Post-IPO | – | – | – |
| Oct 2010 | $3.36M | Post-IPO | – | – | – |
| Dec 2009 | $99,999 | Post-IPO | – | – | – |
| Jul 2009 | $500,000 | Post-IPO | – | – | – |
| Mar 2009 | $450,000 | Post-IPO | – | – | – |
| Dec 2008 | $250,000 | Post-IPO | – | – | – |
| Oct 2008 | $7.52M | Debt – Conventional | – | – | – |
2 investors in total: 2 institutional.
Investors in Napo Pharma
Napo Pharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Jaguar Health and Kingdon Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provides alternative investment management services as a SEC-regulated advisory firm. | 1983 | kingdon.com | New York, United States | |
Novel gastrointestinal products for humans and animals are developed sustainably. | 2013 | jaguar.health | San Francisco, United States |
Investor details for Napo Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Napo India Private Limited (Napo Pharma)
Napo India Private Limited is the primary company behind Napo Pharma. The board of Napo India Private Limited currently have 2 directors; the longest-serving is Lisa Ann Conte, appointed in 2005. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Lisa Ann Conte DIN 02309926 | Director | 29 Dec 2005 | 20 yrs 9 mo | Napo India Private Limited |
| Bobba Venkatadri DIN 02272890 | Director | 17 Sep 2008 | 18 yrs 1 mo | Napo India Private Limited |
People of Napo Pharma
1 people are tracked at Napo Pharma (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Founder & CEO | Leadership |
Complete people profiles for Napo Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Napo Pharma
Figures of Napo India Private Limited, the primary company behind Napo Pharma, for FY 2015. Net loss was -₹41.3 Lakh (0% margin). EBITDA was -₹41 Lakh (0% margin).
- -₹41.3 LakhNet loss · 0% margin
- -₹41 LakhEBITDA · 0% margin
- ₹36.3 LakhPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Napo India Private Limited are on its company page.
Detailed financial statements for Napo Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Napo Pharma
4 dated milestones of Napo Pharma across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Napo Pharma is founded.
- Funding First funding round of $1.6M.
- Funding Latest funding round, Post-IPO, of $2.0M.
- Exit Acquired by Jaguar Health.
Top companies in Gastroenterology
3 companies that operate in the same segment as Napo Pharma (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Napo Pharma
Complete news archive for Napo Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Napo Pharma
Napo Pharma was founded in 2001 and raised its 1st funding round 1 year after it was founded.
Napo Pharma is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Lisa Conte is the CEO of Napo Pharma, as recorded in our data. They have also founded this company.
Napo Pharma is a funded company, having raised a total of $5.14M across 17 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $7.52M, raised on Sep 2002.
Napo Pharmaceuticals was founded in 2001 in San Francisco, United States, where small molecule therapeutics are developed and commercialized for international markets. Emphasis is placed on treatments for diarrheal diseases. Crofelemer has been approved for diarrhea associated with HIVAIDS and licensed to Glenmark and Salix Pharma. Pipeline candidates target insulin-resistant diseases, diarrhea-predominant IBS, acute infectious diarrhea, and pediatric diarrhea.
Napo Pharma offers Mytesi® and NP-300.
Napo Pharma has 2 investors. Key investors include Jaguar Health, and Kingdon Capital Management.
Napo Pharma operates through Napo India Private Limited.
Yes. Napo Pharma was acquired by Jaguar Health in February 2017.
The legal entities of Napo Pharma currently have 2 directors, including Lisa Ann Conte, Bobba Venkatadri.